Oenothein B
Latest Information Update: 29 Jul 1998
Price :
$50 *
At a glance
- Originator Hokuriku University
- Class Antineoplastics; Macrocyclic compounds
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 29 Jul 1998 No-Development-Reported for Cancer in Japan (Unknown route)
- 19 Jan 1995 Preclinical development for Cancer in Japan (Unknown route)